Stéphane Bancel, Moderna CEO (AP Images)
July 27, 2020 11:17 AM EDT
Coronavirus

Mod­er­na be­gins first US piv­otal Covid-19 vac­cine study, lands $472M more from BAR­DA

Jason Mast

Editor

Af­ter weeks of buildup and con­tro­ver­sial de­lays, Mod­er­na has launched its piv­otal study to de­ter­mine whether their Covid-19 vac­cine ac­tu­al­ly works. And BAR­DA is com­mit­ting …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times